|Table of Contents|

Identification and functional study of 2C12 monoclonal antibody against gastric cancer stem cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 08
Page:
1386-1390
Research Field:
Publishing date:

Info

Title:
Identification and functional study of 2C12 monoclonal antibody against gastric cancer stem cells
Author(s):
ZHANG Tao1; LI Jianzhou1; MA Xiaojun1; ZHENG Rui2; SHU Xiong2; WANG Miaozhou3
1.The Second People's Hospital of Xining,Qinghai Xining 810003,China;2.Beijing Jishuitan Hospital/Beijing Institute of Traumatology and Orthopedics,Beijing 100035,China;3.Qinghai University Affiliated Hospital,Qinghai Xining 810012,China.
Keywords:
gastric cancer stem cells; monoclonal antibody; sphere formation ability; invasion ability
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.08.002
Abstract:
Objective:To identify functional monoclonal antibody (2C12) that can target gastric cancer stem cells (CSCs) and provide antibody candidate drugs for targeted therapy of gastric CSCs.Methods:Taking gastric cancer cell line SNU-5 as a cell model,the expression of 2C12+ cells from parent cells and sphere cells was detected by flow cytometry.The expression of antigen protein,which was identified by both monoclonal antibody 2C12 and CD90 in SNU-5 cells,was detected by two-color immunofluorescence.Flow cytometry was used to separate 2C12+ cells and 2C12- cells.The spheroidization experiment in serum-free suspension culture and Transwell method were used to detect their self-renewal ability and invasion ability.After SNU-5 sphere cells were treated with 2C12,SNU-5 sphere cells' ability of self-renewal and invasion was detected.Results:The expression of 2C12+ cells from sphere cells was significantly higher than that of parent cells from SNU-5 cells.The cell immunofluorescence analysis showed that the antigen identified by 2C12 and CD90 could be co-localized in SNU-5 cells.Sphere formation abilities in 2C12+ and 2C12- SNU-5 cells were identified (103.3±9.07 vs 50.67±5.86)（P<0.01）.The invasion ability of 2C12+ cells was significantly higher than that of 2C12- cells (209.3±12.9 vs 99.0±3.61)（P<0.01）.The study on functional properties of antibody in vitro illustrated that different concentrations of 2C12 (0 μg/mL,20 μg/mL,40 μg/mL) could significantly inhibit sphere formation of sphere cells from SNU-5 cells (122.0±5.66，83.0±5.66，59.0±4.24),and the inhibition rate reached 31.97% and 51.6%,meanwhile,2C12 could inhibit the invasion ability of sphere cells from SNU-5 cells (178.0±8.49，106.5±5.0，78.0±2.83),and the inhibition rate was 40.17% and 56.18%.Conclusion:2C12 monoclonal antibody is one of functional monoclonal antibodies targeting gastric CSCs,which can significantly inhibit the stem-related characteristics of gastric CSCs,and could be a candidate drug for the targeted therapy of gastric CSCs.

References:

[1] SEXTON RE,ALHALLlAK MN,DIAB M,et al.Gastric cancer: a comprehensive review of current and future treatment strategies［J］.Cancer Metastasis Rev,2020,39(4):1179-1203.
[2] OUE N,SENTANI K,SAKAMOTO N,et al.Molecular carcinogenesis of gastric cancer: Lauren classification,mucin phenotype expression,and cancer stem cells［J］.Int J Clin Oncol,2019,24(7): 771-778.
[3] XIA JY,AADAM AA.Advances in screening and detection of gastric cancer［J］.J Surg Oncol,2022,125(7):1104-1109.
[4] LIU K,QIN M,HUANG J.The prescreening tool for gastric cancer in China［J］.Gut,2020,69(9):1.
[5] JOSHI SS,BADGWELL BD.Current treatment and recent progress in gastric cancer［J］.CA Cancer J Clin,2021,71(3):264-279.
[6] SMYTH EC,NILSSON M,GRABSCH HI,et al.Gastric cancer［J］.Lancet,2020,396(10251):635-648.
[7] BATLLE E,CLEVERS H.Cancer stem cells revisited［J］.Nat Med,2017,23(10):1124-1134.
[8] PAN Y,MA S,CAO K,et al.Therapeutic approaches targeting cancer stem cells［J］.J Cancer Res Ther,2018,14(7):1469-1475.
[9] TESTA U,PELOSI E,CASTELI G.Cancer stem cell targeted therapies［J］.Ann Ist Super Sanita,2020,56(3):336-350.
[10] AHMAD G,AMIJI MM.Cancer stem cell-targeted therapeutics and delivery strategies［J］.Expert Opin Drug Deliv,2017,14(8):997-1008.
[11] SHU X,LIU H,PAN Y,et al.Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines［J］.Mol Cell Biochem,2019,459(1-2):35-47.
[12] DWIVEDI AR,THAKUR A,KUMAR V,et al.Targeting cancer stem cells pathways for the effective treatment of cancer［J］.Curr Drug Targets,2020,21(3):258-278.
[13] SEENEEVASSEN L,BESSEDE E,MEGRAUD F,et al.Gastric cancer: advances in carcinogenesis research and new therapeutic strategies［J］.Int J Mol Sci,2021,22(7):3418.
[14] FU L,BU L,YASUDA T,et al.Gastric cancer stem cells: current insights into the immune microenvironment and therapeutic targets［J］.Biomedicines,2020,8(1):7.
[15] SNEHA S,NAGARE RP,PRIYA SK,et al.Therapeutic antibodies against cancer stem cells: a promising approach［J］.Cancer Immunol Immunother,2017,66(11):1383-1398.

Memo

Memo:
青海省科技厅应用基础研究项目(编号：2020-ZJ-779)
Last Update: 1900-01-01